(Q34678500)

3 August 2017

1 reference

title

Extensive stage small cell lung cancer (English)

1 reference

3 August 2017

Niell HB

1

1 reference

3 August 2017

publication date

1 February 2001

1 reference

Current Treatment Options in Oncology

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

71-76

1 reference

Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada

3 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007/S11864-001-0018-4

Results of therapeutic cranial irradiation in small cell lung cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S11864-001-0018-4

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Cancer statistics, 1999.

1 reference

12 December 2020

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice

1 reference

12 December 2020

Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.

1 reference

12 December 2020

Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

1 reference

12 December 2020

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party

1 reference

12 December 2020

Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.

1 reference

12 December 2020

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial

1 reference

12 December 2020

Recent developments in chemotherapy treatment of small-cell lung cancer.

1 reference

12 December 2020

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities

1 reference

12 December 2020

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

1 reference

12 December 2020

Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome

1 reference

12 December 2020

Etoposide and cisplatin salvage chemotherapy for small cell lung cancer

1 reference

12 December 2020

First-line chemotherapy rechallenge after relapse in small cell lung cancer

1 reference

12 December 2020

Chemotherapy of lung cancer

1 reference

12 December 2020

A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

1 reference

12 December 2020

Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma

1 reference

12 December 2020

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

1 reference

12 December 2020

Multicenter Phase II trial of etoposide in refractory small cell lung cancer

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

The effect of CNS metastases on the survival of patients with small cell cancer of the lung

1 reference

12 December 2020

Keynote address on biostatistics and data retrieval.

1 reference

12 December 2020

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Staging, prognostic factors, and special considerations in small cell lung cancer.

1 reference

12 December 2020

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

12 December 2020

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

12 December 2020

Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer

1 reference

12 December 2020

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

12 December 2020

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

12 December 2020

Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study

1 reference

12 December 2020

Carboplatin in the Treatment of Small Cell Lung Cancer

1 reference

12 December 2020

Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

12 December 2020

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

12 December 2020

A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer

1 reference

12 December 2020

Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop

1 reference

12 December 2020

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

12 December 2020

10.1007/S11864-001-0018-4

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1031351162

0 references

1 reference